TY - JOUR
T1 - The role of preoperative CEA in the management of colorectal cancer
T2 - A cohort study from two cancer centres
AU - Baqar, Ali Riaz
AU - Wilkins, Simon
AU - Staples, Margaret
AU - Angus Lee, Chun Hin
AU - Oliva, Karen
AU - McMurrick, Paul
PY - 2019/4
Y1 - 2019/4
N2 - Background: The primary aim of this study was to investigate whether a preoperative elevation in serum CEA is an independent prognostic factor for both 5-year overall and disease-free survival within an Australian patient cohort. Materials and methods: A retrospective study of a prospectively maintained colorectal neoplasia database for patients between January 2010 and June 2016 was performed. Patients were categorized into two groups according to the preoperative serum CEA level: low (<2.5), high CEA (≥2.5), and elevated (≥5 ng/ml); and further stratified by disease stage. Inclusion criteria were patients having had a resection for either a colonic or upper third rectal adenocarcinoma and with a preoperative CEA value. Data on patient demographics, mortality, and morbidity and survival were compiled. Five-year estimates of overall (OS) and disease-free survival (DFS) were assessed. Results: 623 patients met the inclusion criteria. The median patient age was 73 (range 22–97) and 55% female (n = 340). There were 572 colonic cancers and 51 rectal cancers. The median follow-up time was 25 months (range 1–71). Eight patients (1%) had a local recurrence and 62 patients (10%) had evidence of metastatic disease after the initial curative resection. The 5-year OS and DFS rates for patients with CEA level <2.5 ng/ml were 85% and 86% respectively, which were higher than those with CEA level ≥2.5 ng/ml (73% and 79% respectively). Independent predictors of recurrence were a CEA ≥5 ng/ml (HR 1.8; 95% CI 1.09–3.00; p = 0.002) and stage II (HR 5.33; 95% CI 1.59–17.90; p = 0.007) and stage III (HR 10.91; 95% CI 3.34–35.60; p=<0.001). A CEA ≥5 ng/ml was associated with a higher risk of death (HR 1.79; 95% CI 1.00–3.19; p = 0.046). Conclusion: Preoperative CEA levels were associated with age, BMI, ASA and tumour stage. Overall, CEA remains a reliable predictor of recurrence and survival after curative surgery in patients with colorectal cancer.
AB - Background: The primary aim of this study was to investigate whether a preoperative elevation in serum CEA is an independent prognostic factor for both 5-year overall and disease-free survival within an Australian patient cohort. Materials and methods: A retrospective study of a prospectively maintained colorectal neoplasia database for patients between January 2010 and June 2016 was performed. Patients were categorized into two groups according to the preoperative serum CEA level: low (<2.5), high CEA (≥2.5), and elevated (≥5 ng/ml); and further stratified by disease stage. Inclusion criteria were patients having had a resection for either a colonic or upper third rectal adenocarcinoma and with a preoperative CEA value. Data on patient demographics, mortality, and morbidity and survival were compiled. Five-year estimates of overall (OS) and disease-free survival (DFS) were assessed. Results: 623 patients met the inclusion criteria. The median patient age was 73 (range 22–97) and 55% female (n = 340). There were 572 colonic cancers and 51 rectal cancers. The median follow-up time was 25 months (range 1–71). Eight patients (1%) had a local recurrence and 62 patients (10%) had evidence of metastatic disease after the initial curative resection. The 5-year OS and DFS rates for patients with CEA level <2.5 ng/ml were 85% and 86% respectively, which were higher than those with CEA level ≥2.5 ng/ml (73% and 79% respectively). Independent predictors of recurrence were a CEA ≥5 ng/ml (HR 1.8; 95% CI 1.09–3.00; p = 0.002) and stage II (HR 5.33; 95% CI 1.59–17.90; p = 0.007) and stage III (HR 10.91; 95% CI 3.34–35.60; p=<0.001). A CEA ≥5 ng/ml was associated with a higher risk of death (HR 1.79; 95% CI 1.00–3.19; p = 0.046). Conclusion: Preoperative CEA levels were associated with age, BMI, ASA and tumour stage. Overall, CEA remains a reliable predictor of recurrence and survival after curative surgery in patients with colorectal cancer.
KW - Carcinoembryonic antigen
KW - Colorectal cancer
KW - Prognostic testing
KW - Survival
UR - https://www.scopus.com/pages/publications/85062268268
U2 - 10.1016/j.ijsu.2019.02.014
DO - 10.1016/j.ijsu.2019.02.014
M3 - Article
AN - SCOPUS:85062268268
SN - 1743-9191
VL - 64
SP - 10
EP - 15
JO - International Journal of Surgery
JF - International Journal of Surgery
ER -
